Ulf Nehrbass

Amministratore Delegato presso Luxembourg Institute of Health

Health Technology

Commercial Services

Profilo

Ulf Nehrbass is currently the Chief Executive Officer at Luxembourg Institute of Health.
Previously, he held the same position at Qurient Co., Ltd.

Posizioni attive di Ulf Nehrbass

Società	Posizione	Inizio
Luxembourg Institute of Health Luxembourg Institute of Health Miscellaneous Commercial ServicesCommercial Services Luxembourg Institute of Health (LIH) is an interdisciplinary research organization that focuses on identifying environmental, lifestyle, and behavioral factors affecting health. The private company is based in Strassen, Luxembourg. LIH uses its expertise in digital epidemiology, human biomonitoring, sport medicine, nutrition, and molecular biology to support the implementation and evaluation of new e-health technologies in the context of disease prevention and improving population health. Cancer is a priority disease for LIH, and Precision Oncology is at the heart of their efforts. The CEO of the Luxembourger company is Ulf Nehrbass.	Amministratore Delegato	-

Tutte le posizioni attive di Ulf Nehrbass

Precedenti posizioni note di Ulf Nehrbass

Società	Posizione	Fine
QURIENT CO., LTD.	Amministratore Delegato	-

Vedi nel dettaglio l'esperienza di Ulf Nehrbass

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Ulf Nehrbass

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
QURIENT CO., LTD.	Health Technology

Aziende private	1
Luxembourg Institute of Health Luxembourg Institute of Health Miscellaneous Commercial ServicesCommercial Services Luxembourg Institute of Health (LIH) is an interdisciplinary research organization that focuses on identifying environmental, lifestyle, and behavioral factors affecting health. The private company is based in Strassen, Luxembourg. LIH uses its expertise in digital epidemiology, human biomonitoring, sport medicine, nutrition, and molecular biology to support the implementation and evaluation of new e-health technologies in the context of disease prevention and improving population health. Cancer is a priority disease for LIH, and Precision Oncology is at the heart of their efforts. The CEO of the Luxembourger company is Ulf Nehrbass.	Commercial Services